CHICAGO & WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the presentation of further data from the Company’s randomized, international Phase 2b investigational study of FOLOTYN® (pralatrexate injection) relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. The presentation, which includes additional results from several pre-specified analyses, reinforces the favorable survival data observed with FOLOTYN in patients with advanced NSCLC—including outcomes observed in patients with non-squamous and squamous histologies, as well as results from an analysis adjusting for important baseline factors and potential imbalances in the number of patients between cohorts.
